Gilead Sciences (NASDAQ: GILD)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Gilead Sciences Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Gilead Sciences Company Info
Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.
News & Analysis
How Many Small-Cap Stocks Are There?
The number changes quickly.
3 No-Brainer Dividend Stocks to Buy in September
Income investors should really like these biopharma stocks with juicy dividends.
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
These stocks are built to withstand a bear market.
Top ETFs Tracking CRISPR Gene Editing
These exchange-traded funds track companies in this biotech space.
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade.
2 Top Biotech Stocks to Buy in June
Both companies have solid therapy franchises and continue to expand their horizons.
20 High-Yield Dividend Stocks to Buy in 2023
A list of high-yielding dividend stocks to consider buying now.
Investing in Biotech ETFs
Here are the five best biotech ETFs to invest in right now.
Valuation
Podcast Episodes
What Happened With CAR-T Stocks in 2018
Here’s how CAR-T therapies did in their first full year on the market.
Should You Stick With Gilead Sciences?
Declining sales increase the stakes for Gilead's most-promising R&D projects.
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
Celgene vs. Gilead Sciences: Who Reported Better Earnings?
Celgene's and Gilead Sciences’ Q2 2017 results are fueling gains in their stock prices, but is one of these stocks doing better than the other?
Earnings Transcripts
Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript
GILD earnings call for the period ending June 30, 2023.
Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript
GILD earnings call for the period ending March 31, 2023.
Gilead Sciences (GILD) Q4 2022 Earnings Call Transcript
GILD earnings call for the period ending December 31, 2022.
Gilead Sciences (GILD) Q3 2022 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.